Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis. According to GlobalData, Phase I drugs for Osteoporosis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Anti-RANKL Monoclonal Antibody’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anti-RANKL Monoclonal Antibody overview
The therapeutic candidate is under development for the treatment of osteoporosis and myeloma. It is a monoclonal antibody which acts by targeting receptor activator of nuclear factor kappa-B ligand (RANKL).
Jiangsu Pacific Meinuoke Bio-Pharmarceutical overview
Jiangsu Pacific Meinuoke Bio-Pharmarceutical (Pacific Meinuoke) focuses on the development of novel biopharmaceuticals for addressing the unmet medical needs of patients with cancer and infectious diseases. Pacific Meinuoke is headquartered in Changzhou City, China.
For a complete picture of Anti-RANKL Monoclonal Antibody’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
